BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Awiqli (insulin icodec) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Awiqli (insulin icodec)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07076199-319@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Awiqli (insulin icodec): Phase 3 readout est. (NCT07076199)
DESCRIPTION:Awiqli (insulin icodec)\, phase 3.\nStudy: A Research Study to 
 See How a Weekly Insulin\, Insulin Icodec\, Helps in Reducing the Blood Su
 gar Compared to Daily Insulin Glargine\, Both in Combination With Insulin 
 Aspart\, in Adults With Type 1 Diabetes\nEstimated primary completion: 25 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/insulin
 -icodec#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07076199
URL:https://assetmemo.bio/drug/insulin-icodec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591519-319@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Awiqli (insulin icodec): Phase 1 readout est. (NCT07591519)
DESCRIPTION:Awiqli (insulin icodec)\, phase 1.\nStudy: Clinical Trials of I
 BI3035 in Healthy Subjects\nEstimated primary completion: 30 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/insulin-icodec#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07591519
URL:https://assetmemo.bio/drug/insulin-icodec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747402-319@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Awiqli (insulin icodec): Phase 4 readout est. (NCT07747402)
DESCRIPTION:Awiqli (insulin icodec)\, phase 4\, Type 2 Diabetes.\nStudy: In
 sulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2
  Diabetes\nEstimated primary completion: October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/insulin-icodec#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07747402
URL:https://assetmemo.bio/drug/insulin-icodec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112339-319@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20280323
DTEND;VALUE=DATE:20280324
SUMMARY:Awiqli (insulin icodec): Phase 4 readout est. (NCT07112339)
DESCRIPTION:Awiqli (insulin icodec)\, phase 4\, Type 2 Diabetes.\nStudy: A 
 Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar
  Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes\nE
 stimated primary completion: 23 March 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/insulin-icodec#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07112339
URL:https://assetmemo.bio/drug/insulin-icodec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
